Advanced-stage pancreatic cancer currently has no effective treatment—most patients are told there’s nothing that can be done. Carboxamil is a groundbreaking new therapy that could change that. It’s the first non-toxic treatment with no major side effects, offering a safer, smarter way to fight this deadly disease. By targeting only cancer cells and sparing healthy ones, Carboxamil gives patients a real chance to live. This could be the breakthrough that brings hope where none has existed.
SHARE:
At Vitalgenics, we’re taking on one of the deadliest cancers—advanced-stage pancreatic cancer—where the current reality is grim: there is no true standard of care, and for most patients, the outcome is death.
Traditional chemotherapy is delivered throughout the entire body, damaging healthy cells and causing severe side effects like hair loss, infections, and immune system failure. These side effects are so debilitating that many patients quit treatment altogether. Worse, less than 3% of these drugs ever reach the actual tumor.
We created Carboxamil to do what no other treatment has done for advanced-stage pancreatic cancer. It’s a non-toxic, side-effect–free therapy that reaches 100% of the tumor, giving the immune system a real chance to fight back. There’s no hair loss, no infections, and no damage to healthy cells.
Carboxamil is based on an already FDA-approved drug with a strong safety record—but we’ve repurposed it to target pancreatic cancer. It works by blocking a key cancer activator called GPCR35. When Carboxamil locks onto this receptor, it stops cancer from growing at the source, allowing the immune system to find and destroy the tumors.
Unlike standard chemo delivered through an IV port, Carboxamil travels through the arterial system, where oxygen-rich blood flows straight to the tumor. This means the drug avoids healthy cells and concentrates where it’s needed most.
Think of pancreatic cancer as a faucet turned on full blast, flooding your body. Most treatments don’t even reach the faucet. Carboxamil turns it off.
Pancreatic cancer is aggressive. Time is everything. Every day that goes by without effective treatment means more lives lost. With Carboxamil, we finally have a real weapon—one that’s smarter, safer, and radically more effective.
We’re gearing up for two critical next steps in bringing Carboxamil to patients fighting advanced-stage pancreatic cancer:
Here’s a breakdown of how the $250,000 from this campaign will be used:
| Use | Amount | Details |
|---|---|---|
| FDA IND Submission | $50,000 | Includes FDA pre-IND meeting and electronic submission of safety and drug data |
| Proof-of-Concept Study | $200,000 | Conducted in partnership with the University of Louisville and Brown Cancer Center. Covers patient care, data collection, procedures, and six-month follow-up |
| TOTAL | $250,000 |
We’ve already lined up the key partners and tools needed to make this next phase happen:
Clinical Collaboration: University of Louisville and Brown Cancer Center are on board. The study protocol has already been reviewed by their ethics (IRB) committee, and study staff are in place.
Regulatory Support: We’ve contracted with a seasoned FDA regulatory consultant who will lead our pre-IND meeting and formal IND submission.
Drug Supply: Our active drug ingredient has been provided by Olon Pharmaceuticals.
Delivery Technology: The precision drug delivery device is provided by Embolx.
Final Drug Formulation: Prepared and packaged by VPI Pharmacy.
For far too long, people diagnosed with advanced-stage pancreatic cancer have faced a devastating truth: there’s nothing that can save them.
That Could Finally Change.
Carboxamil offers a breakthrough—the first non-toxic treatment with no major side effects for advanced-stage pancreatic cancer. Unlike traditional chemotherapy, it doesn’t damage healthy cells, and it doesn’t make people sicker while fighting to survive.
Carboxamil brings something patients have never had before: real hope—the hope that they can live.
The Future of Pancreatic Cancer Treatment
Co-founder & CFO
An applied scientist focused on multidrug resistance Pancreatic cancer , bacterial infection, cell mediated immunity. A clear understanding of the cell mediated immune stress response cascade, Ca2+, the inflammatory response and how these relate to Multidrug resistance Pancreatic cancer and bacterial infection, cell- mediated immune diseases and target organ therapy. He is experienced in research and development, clinical study protocols, toxicity studies, target therapy drug delivery applications.
Co-founder & CEO
has had a very successful career as an innovative leader. He is focused on achieving positive results through strong leadership, effective communication, interpersonal relations, and excellent analytical skills. His successes have been the result of disrupting the status quo and revolutionizing normal thinking and processes. His innovative and pragmatic approach has led to developing strategic partnerships and synergies with functional leaders to effectively bridge the gap between the needs of clients, business objectives, operational decisions, and financial targets while continuing to contain costs and drive profitable growth
Chief Scientific Officer
Pancreatic Cancer Researcher -Retired from MD nAnderson Cancer Center to hold the dis tinguished position as Lockton Distinguished Chair for Pancreatic Cancer. He served as Professor in the Department of Gastrointestinal in Medical Oncology and as Professor in the Department of Cancer Biology. He has served as the past President of the American Pancreatic Association, the Scientific Advisory Board of the National Pancreas Foundation, and served on the Scientific Advisory Board of the Pancreatic Cancer Action Network (PanCan). Association. He has published 137 Peer-Reviewed original research articles, 19 Invited articles and was the cocreator of 2 patents.
$100 donated by Anonymous
